MedPath

The effects of sitagliptin as a DPPIV inhibitor on vascular endothelial and autonomic nerve functions in patients with type II diabetes mellitus.

Not Applicable
Conditions
Type II diabetes mellitus
Registration Number
JPRN-UMIN000004236
Lead Sponsor
ippon Medical School Department of Medicine Division of Cardiology, Hepatology,Geriatrics and Integrated Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) Type I diabetes mellitus 2) Patients receiving insulin therapy 3) Severe renal dysfunction requiring hemodialysis or peritoneal dialysis 4) Severe hepatopathy/nephropathy or heart disease that may affect the evaluation of drug safety 5) Patients who are deemed to be inappropriate by the investigator or sub-investigators

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Flow mediated dilation (FMD)
Secondary Outcome Measures
NameTimeMethod
HbA1c, fasting blood glucose, autonomic nerve function
© Copyright 2025. All Rights Reserved by MedPath